Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Esophageal Carcinoma

Esophageal Carcinoma

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Esophageal Carcinoma

10 trials tracked for Esophageal Carcinoma: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 1184 citations.

10Trials tracked
3Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 3 Phase 2 6 Other / NA 1
  1. Phase 3 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Completed · 1,184 cited
  2. Phase 3 Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer Completed · 584 cited
  3. Phase 3 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study Completed · 55 cited
  4. Phase 2 Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma Completed
  5. Phase 2 Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia Completed
  6. Phase 2 Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer Completed
Show 4 more trials
  1. Phase 2 Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan. Completed
  2. Phase 2 Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer Completed
  3. Phase 2 Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) Completed
  4. N/A Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Esophageal Carcinoma: what the trials found

Pembrolizumab has demonstrated statistically significant improvements in Overall Survival (OS) for patients with esophageal squamous cell carcinoma (SCC). In one study, OS was 8.2 vs. 7.1 months (p=0.00894) 2, and in another, it was 8.4 vs. 5.6 months (p=0.0021) 4.

Furthermore, pembrolizumab showed significant OS benefits specifically in patients with a Programmed Death-Ligand 1 Combined Positive Score of $\geq$10 (PD-L1 CPS $\geq$10). Outcomes included 9.3 vs. 6.7 months (p=0.00855) 2 and 12.0 vs. 5.3 months (p=0.0008) 4. Other trials evaluated pembrolizumab in this patient population but did not report specific survival metrics 6.

Recent results — preliminary, needs further review

  • Acupuncture therapy was evaluated for the management of chemotherapy-induced peripheral neuropathy (CIPN). Results showed a change in severity scores and reported counts of patients with Grade 2 or higher CIPN, though specific p-values for these secondary outcomes were not provided 1.

For the clinician treating this condition

  • Pembrolizumab is associated with improved Overall Survival in esophageal squamous cell carcinoma, particularly in patients with PD-L1 CPS $\geq$10.
  • Acupuncture therapy has been investigated as a supportive intervention for chemotherapy-induced peripheral neuropathy.

AI synthesis of 4 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Preoperative chemoradiotherapy increases R0 resection and pathologic complete response rates in esophageal carcinoma
Oncology Meta-analysis
Preoperative chemoradiotherapy increases R0 resection and pathologic complete response rates in esophageal carcinoma Radiotherapy Combined with Chemotherapy Shows Better Local Control for Cancer
This meta-analysis of randomized controlled trials compared perioperative chemotherapy to preoperative chemoradiotherapy for resectable esop…
Combining chemotherapy and radiation before surgery may improve tumor clearance rates for patients with esophageal or gastroesophageal junct…
Jul 3, 2026
SIB-RT plus S-1 improves survival in elderly inoperable esophageal cancer
ENT (Otolaryngology) RCT
SIB-RT plus S-1 improves survival in elderly inoperable esophageal cancer Combination therapy improves survival in older esophageal cancer patients
This phase III multicenter RCT compared simultaneous integrated boost radiotherapy plus oral S-1 (CRTCT) to radiotherapy alone in patients a…
Adding chemo to radiation boosts 5-year survival from 24% to 34% in older patients with inoperable esophageal cancer.
May 1, 2026